Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2013 Jul;9(7):371-81.
doi: 10.1038/nrneurol.2013.107. Epub 2013 Jun 11.

Ushering in the study and treatment of preclinical Alzheimer disease

Jessica B Langbaum  1 , Adam S Fleisher, Kewei Chen, Napatkamon Ayutyanont, Francisco Lopera, Yakeel T Quiroz, Richard J Caselli, Pierre N Tariot, Eric M Reiman
Affiliations
Review

Ushering in the study and treatment of preclinical Alzheimer disease

Jessica B Langbaum et al. Nat Rev Neurol. 2013 Jul.

Erratum in

  • Nat Rev Neurol. 2013 Aug;9(8):418

Abstract

Researchers have begun to characterize the subtle biological and cognitive processes that precede the clinical onset of Alzheimer disease (AD), and to set the stage for accelerated evaluation of experimental treatments to delay the onset, reduce the risk of, or completely prevent clinical decline. In this Review, we provide an overview of the experimental strategies, and brain imaging and cerebrospinal fluid biomarker measures that are used in early detection and tracking of AD, highlighting at-risk individuals who could be suitable for preclinical monitoring. We discuss how advances in the field have contributed to reconceptualization of AD as a sequence of biological changes that occur during progression from preclinical AD, to mild cognitive impairment and finally dementia, and we review recently proposed research criteria for preclinical AD. Advances in the study of preclinical AD have driven the recognition that efficacy of at least some AD therapies may depend on initiation of treatment before clinical manifestation of disease, leading to a new era of AD prevention research.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Reconceptualizing Alzheimer’s Disease
Figure 2
Figure 2
Well Established Brain Imaging Techniques in the Detection and Tracking of AD
Figure 3
Figure 3
Hypothetical dynamic biomarkers of the AD pathological cascade
Figure 4
Figure 4
Temporal link between amyloid deposition and onset of AD dementia With permission from Chris Rowe, reprinted from
See this image and copyright information in PMC

References

    1. Alzheimer's Association 2012 Alzheimer's disease facts and figures. Alzheimers Dement. 2012;8:131–168. - PubMed
    1. Corrada MM, Brookmeyer R, Paganini-Hill A, Berlau D, Kawas CH. Dementia incidence continues to increase with age in the oldest old: The 90+study. Ann. Neurol. 2010;67:114–121. - PMC - PubMed
    1. Brookmeyer R, et al. National estimates of the prevalence of Alzheimer's disease in the United States. Alzheimer's & dementia: the journal of the Alzheimer's Association. 2011;7(1):61–73. - PMC - PubMed
    1. Hebert LE, Beckett LA, Scherr PA, Evans DA. Annual incidence of Alzheimer disease in the United States projected to the years 2000 through 2050. Alzheimer Dis. Assoc. Disord. 2001;15:169–173. - PubMed
    1. Reiman EM, Langbaum JBS. Brain imaging in the evaluation of putative Alzheimer's disease slowing, risk-reducing and prevention therapies. In: Jagust WJ, D'Esposito M, editors. Imaging the Aging Brain. New York: Oxford University Press; 2009. pp. 319–350.

Publication types